Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

<h4>Background</h4>In Canada and elsewhere, pazopanib and sunitinib-tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors-are recommended as first-line treatment for patients with metastatic renal cell carcinoma (mrcc). A large randomized noninferiority trial of pazop... View More